PLCG1 - Phospholipase C Gamma 1

PLCG1 - Phospholipase C Gamma 1

Introduction

PLCG1 (Phospholipase C Gamma 1) encodes a key signaling enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This phospholipase C isoform is uniquely activated by receptor tyrosine kinases (RTKs) via its tandem SH2 domains, making it a critical bridge between growth factor signaling and intracellular calcium mobilization. In the brain, PLCG1 participates in synaptic transmission, neuronal development, and neuroplasticity, while dysregulation contributes to neurodegenerative disease pathogenesis.

Gene Information

PLCG1 - Phospholipase C Gamma 1

Introduction

PLCG1 (Phospholipase C Gamma 1) encodes a key signaling enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This phospholipase C isoform is uniquely activated by receptor tyrosine kinases (RTKs) via its tandem SH2 domains, making it a critical bridge between growth factor signaling and intracellular calcium mobilization. In the brain, PLCG1 participates in synaptic transmission, neuronal development, and neuroplasticity, while dysregulation contributes to neurodegenerative disease pathogenesis.

Gene Information

<div class="infobox infobox-gene">
<div class="infobox-header">Gene Information</div>
<div class="infobox-content"> Symbol: PLCG1 Full Name: Phospholipase C Gamma 1 Chromosomal Location: 20q12-q13.11 NCBI Gene ID: [5335](https://www.ncbi.nlm.nih.gov/gene/5335) OMIM: [172420](https://www.omim.org/entry/172420) Ensembl ID: ENSG00000124181 UniProt ID: [P19174](https://www.uniprot.org/uniprot/P19174) Associated Diseases: Alzheimer's disease, Parkinson's disease, Schizophrenia, Cancer
</div>
</div>

Protein Structure and Function

Catalytic Domains

PLCG1 is a 1290-amino acid protein with a modular domain architecture[@gresset2010]:

• X domain: Phosphorylase C-like phosphodiesterase core that catalyzes PIP2 hydrolysis
• Y domain: Regulatory accessory domain required for catalytic activity
• C2 domain: Calcium-dependent membrane targeting
• SH2 domain (x2): Tandem Src homology 2 domains for RTK binding and phosphotyrosine recognition
• SH3 domain: Proline-rich region for cytoskeletal protein interactions

Activation Mechanism

PLCG1 activation involves multiple steps[@hardie1995]:

Second Messenger Generation

Activated PLCg1 produces two crucial second messengers[@berridge1993]:

• DAG: Remains in the membrane, activates protein kinase C (PKC) and related kinases
• IP3: Diffuses to the endoplasmic reticulum, triggering calcium release via IP3 receptors

Role in Neurodegeneration

Alzheimer's Disease

PLCG1 is heavily implicated in Alzheimer's disease pathogenesis through multiple mechanisms[@querfurth2010]:

• APP processing: PLCg1 influences amyloid precursor protein (APP) processing through PKC-dependent pathways. PKC activation promotes non-amyloidogenic alpha-secretase cleavage, while PLCg1 dysregulation shifts processing toward amyloidogenic beta- and gamma-secretase pathways[@cao2012].
• Calcium dysregulation: Aβ oligomers cause excessive PLCg1 activation, leading to IP3-mediated calcium release from ER stores. This calcium dysregulation contributes to excitotoxicity and neuronal death[@demuro2011].
• Synaptic dysfunction: PLCg1-mediated signaling is essential for synaptic plasticity. In AD, Aβ-induced PLCg1 hyperactivation disrupts long-term potentiation (LTP) and memory formation[@shankar2008].
• Tau pathology: PKC activation by DAG modulates GSK-3β activity, directly affecting tau phosphorylation. PLCg1 dysregulation thus contributes to neurofibrillary tangle formation[@gong2004].

Parkinson's Disease

In Parkinson's disease, PLCg1 participates in[@plattner2020]:

• Dopaminergic signaling: PLCg1 modulates dopamine receptor signaling in striatal medium spiny neurons. Dysregulation affects motor control and reward processing.
• α-Synuclein aggregation: Calcium dysregulation caused by PLCg1 hyperactivation promotes α-synuclein aggregation and toxicity[@calo2016].
• Mitochondrial dysfunction: PLCg1-mediated calcium signals influence mitochondrial health and can trigger apoptotic pathways in dopaminergic neurons.

Amyotrophic Lateral Sclerosis

PLCG1 variants and dysregulation have been linked to ALS[@ferraiuolo2011]:

• Motor neuron vulnerability: PLCg1 signaling affects excitability and survival of motor neurons
• Glial contributions: Astrocytic PLCg1 regulates glutamate uptake; dysregulation contributes to excitotoxicity
• TDP-43 pathology: PLCg1 interacts with RNA granules; its dysregulation may contribute to TDP-43 aggregation

Synaptic Function

Neurotransmitter Release

PLCG1 plays essential roles in synaptic transmission[@brose1992]:

• Presynaptic vesicle release: IP3-mediated calcium release modulates vesicle fusion and neurotransmitter release
• Synaptic plasticity: DAG-PKC signaling is crucial for LTP and long-term depression (LTD)
• Retrograde signaling: Endocannabinoid release involves PLCg1-dependent pathways

Receptor Signaling

PLCG1 integrates signals from multiple receptor types:

| Receptor | PLCg1 Role | Neurobiological Effect |
|----------|-----------|----------------------|
| TrkA/B | Direct activation | NGF/BDNF signaling |
| EGFR | Indirect activation | Growth factor responses |
| mGluR1/5 | Gq-coupled activation | Glutamate signaling |
| 5-HT2A | Gq-coupled activation | Serotonin modulation |
| D1/D5 | Gq-coupled activation | Dopamine modulation |

Therapeutic Implications

Targeting PLCg1

PLCG1 represents a therapeutic target for neurodegenerative diseases[@gurley1996]:

• PKC inhibitors: PKC modulators indirectly affect PLCg1 downstream signaling
• IP3 receptor antagonists: Drugs targeting IP3 receptors can prevent excessive calcium release
• Calcium stabilizers: Compounds that buffer intracellular calcium may counteract PLCg1 dysregulation

Small Molecule Inhibitors

Several PLC inhibitors have been developed:

• U73122: Classic PLC inhibitor, though limited by poor selectivity
• Edelfosine: Alkylphospholipid that inhibits PLCg1
• D609: Selective for PLCg1 over other PLC isoforms

Protein Interactions

Kinase Interactions

| Protein | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| PDGFR | Direct binding | Growth factor activation |
| EGFR | Direct binding | Growth factor activation |
| TrkA | Direct binding | NGF signaling |
| PKCα | DAG-dependent | Signal transduction |
| Src | Tyrosine phosphorylation | Activation regulation |

Scaffold Proteins

• LAT: Linker for activation of T cells, scaffolds PLCg1 in immune cells
• SLP-76: Cooperates with LAT in signaling complexes
• Grb2: Adapter protein that recruits PLCg1 to RTKs

Expression Patterns

Brain Regional Distribution

PLCG1 is widely expressed in the brain with highest levels in[@huntsman1999]:

• Hippocampus: Particularly CA1 and dentate gyrus, regions critical for memory
• Cerebral cortex: Layer-specific expression patterns
• Cerebellum: Purkinje cells show high expression
• Striatum: Medium spiny neurons express PLCg1

Cell Type Distribution

• Neurons: High expression in excitatory and inhibitory neurons
• Astrocytes: Moderate expression, participates in calcium signaling
• Microglia: Activation-dependent expression
• Oligodendrocytes: Myelination-associated expression

Signaling Pathways

Downstream Effects

PLCG1 activation triggers multiple signaling cascades[@watt2019]:

Growth Factor → RTK → PLCg1 → DAG + IP3
↓
┌──────┴──────┐
↓ ↓
PKC Activation Ca²⁺ Release
↓ ↓
┌──────┴──────┐ ↓
↓ ↓ ↓
MAPK/ERK Gene Expression Exocytosis
Activation (CREB) Synaptic Transmission

Cross-talk with Other Pathways

PLCG1 interacts with numerous signaling pathways:

• MAPK/ERK pathway: PKC activation leads to Raf/MEK/ERK activation
• PI3K/Akt pathway: Cross-talk regulates cell survival
• Calcium/calmodulin pathways: Calcium influx activates calcineurin and CaMKII

Genetic Associations

Neurodegenerative Disease Variants

| Disease | Variant | Effect | Reference |
|---------|---------|--------|----------|
| Alzheimer's disease | rs2293309 | Risk modification | GWAS |
| Parkinson's disease | rs1249768 | Altered expression | eQTL study |
| Schizophrenia | rs6011300 | Association | GWAS |

Research Directions

Biomarker Potential

PLCG1 activity in cerebrospinal fluid may serve as a biomarker for synaptic dysfunction in neurodegenerative diseases[@plcg2022]. Phosphorylated PLCg1 levels correlate with disease severity in some contexts.

Model Systems

• Knockout mice: Plcg1 knockout is embryonic lethal; conditional knockouts reveal neuronal functions
• iPSC models: Patient-derived neurons allow study of PLCg1 variants
• Organoid systems: Brain organoids reveal developmental roles

Disease Associations

Top DisGeNET gene-disease associations for this gene are listed below. Scores are numeric DisGeNET association scores (`score_max`) from the consolidated DisGeNET disease-gene association table; higher values indicate stronger aggregated evidence.

| Disease | DisGeNET score | Evidence sources | Supporting PMID count |
|---|---:|---|---:|
| sarcoma | 0.211 | BeFree/CTD_human | 2 |
| bipolar disorder | 0.005 | BeFree/GAD | 2 |
| hematologic cancer | 0.003 | BeFree/LHGDN | 2 |
| multiple sclerosis | 0.002 | GAD | 1 |
| prostate cancer | 0.001 | BeFree | 3 |

Source: DisGeNET-derived consolidated disease-gene associations (`dhimmel/disgenet`, gene symbol `PLCG1`).

See Also

• [Phospholipase C Signaling](/mechanisms/phospholipase-c-signaling)
• [Calcium Signaling in Neurodegeneration](/mechanisms/calcium-dysregulation-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity-neurodegeneration)
• [APP Processing](/mechanisms/app-processing-amyloid)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PLCG1 - Phospholipase C Gamma 1 discovered through SciDEX knowledge graph analysis: